Theratechnologies Inc. (NASDAQ:THTX) Earnings Conference Call July 10, 2024 8:30 AM ET
Company Participants
John Leasure - Global Commercial Officer
Paul Levesque - President & CEO
Philippe Dubuc - SVP & CFO
Christian Marsolais - SVP & Chief Medical Officer
Conference Call Participants
Andre Uddin - Research Capital
Justin Walsh - JonesTrading
Carvey Leung - Cantor Fitzgerald
Operator
Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Theratechnologies Second Quarter 2024 Earnings Call. We would like to remind everyone that all figures on this call are quoted in U.S. dollars. At this time, all participants are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session with analysts. Instructions will be provided at that time for you to queue up for questions.
Following the analyst Q&A session, investors wishing to submit a question may do so by clicking the Ask a Question link on the webcast platform. [Operator Instructions] I would like to remind everyone that this conference call is being recorded today, Wednesday, July 10th, 2024, at 8.30 a.m. Eastern Time.
I will now turn the call over to John Leasure, Global Commercial Officer at Theratechnologies. John, please go ahead.
John Leasure
Thank you, operator, and good morning, everyone. On the call today will be Theratechnologies President and Chief Executive Officer, Mr. Paul Levesque; and Senior Vice President and Chief Financial Officer, Mr. Philippe Dubuc. During the Q&A session, he'll be joined by Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer, and myself, the company's Global Commercial Officer.
Before we begin, I'd like to remind everyone that remarks today contain forward-looking statements regarding the company's current and future plans, expectations, and intentions with respect to future events. Forward-looking statements are based on assumptions, and there are risks that results obtained by Theratechnologies may differ materially from those statements. As such, the company cannot guarantee that any forward-looking statement will materialize, and you are cautioned not to place undue reliance on them. The company refers current and potential investors to the forward-looking information section of Theratechnologies’ Management’s Discussion and Analysis, issued this morning and available on SEDAR at www. sedarplus.ca, and on EDGAR at www.sec.gov. Forward-looking statements represent Theratechnologies expectations as of this morning, July 10, 2024.
Additionally, today the company is using the term adjusted EBITDA, which is not a financial measure under International Financial Reporting Standards, IFRS, or U.S. Generally Accepted Accounting Principles, U.S. GAAP. Adjusted EBITDA excludes the effects of items that primarily reflect the impact of long-term investment and financing decisions rather than the results of day-to-day operations. Theratechnologies believes that this measure can be a useful indicator of its operational performance and financial condition from one period to another. Company uses this non-IFRS measures to make financial, strategic, and operating decisions. Reconciliation of adjusted EBITDA to net loss is found in our MD&A issued this morning, available on SEDAR and on EDGAR at the web addresses mentioned earlier. Investors can also follow the company on LinkedIn and X and sign up for alerts on Theratechnologies investor website at theratech.com.